Chemical Research in Toxicology
November 19, 1999
Fengju Bai, Serrine S. Lau, Terrence J. Monks
109 citations
Direct injection of either 3,4-(+/-)-methylenedioxymethamphetamine (MDMA) or 3,4-(+/-)-methylenedioxyamphetamine (MDA) into the brain fails to reproduce the serotonergic neurotoxicity seen following peripheral administration. The serotonergic neurotoxicity of MDA and MDMA therefore appears to be dependent upon the generation of a neurotoxic metabolite, or metabolites, the identity of which...
Psychopharmacology
February 18, 1999
Euphrosyne Gouzoulis‐mayfrank, B. Thelen, Elmar Habermeyer et al.
145 citations
The aim of this study was to contribute to the characterization of the entactogen (ecstasy) substance group. The psychopathological, neuroendocrine and autonomic effects of common recreational doses of the entactogen 3,4-methylenedioxyethylamphetamine (MDE), the hallucinogen psilocybin, the stimulant d-methamphetamine and placebo were investigated in a double-blind study with healthy volunteers...
Pharmacopsychiatry
July 1, 1998
K.-A. Kovar
32 citations
Amphetamines, tryptamines, phencyclidines, tetrahydrocannabinol and substances of the ecstasy group are characterized as stimulants, hallucinogens and entactogens. The various effects of each group and their mode of action in different transmitter systems are described. 28 new compounds of the amphetamine and tryptamine series has been calculated, which exceed the hallucinogenic effects of...
Chemical Research in Toxicology
1996
R. Timothy Miller, Serrine S. Lau, Terrence J. Monks
63 citations
alpha-Methyldopamine (alpha-MeDA) is a metabolite of the serotonergic neurotoxicants 3,4-(+/-)-(methylenedioxy)amphetamine (MDA) and 3,4-(+/-)-(methylenedioxy)methamphetamine (MDMA). alpha-MeDA readily oxidizes, and in the presence of glutathione (GSH) it forms 5-(glutathion-S-yl)-alpha-methyldopamine [5-(glutathion-S-yl)-alpha-MeDA]. Since GSH conjugates of many polyphenols are biologically...
American Journal of Psychotherapy
July 1, 1986
Lester Grinspoon, James B. Bakalar
189 citations
Many preindustrial cultures traditionally use certain psychedelic plants to enhance a procedure that resembles psychotherapy--an idea that was also tested in Western psychiatry in the 1950s and 1960s. LSD and related drugs were used to facilitate the production of memories, fantasies and insights and to enhance the therapeutic alliance. The results were inconclusive, and research was largely...
Journal of Psychoactive Drugs
October 1, 1985
David E. Smith, Richard B. Seymour
14 citations
(1985). Dream Becomes Nightmare: Adverse Reactions to LSD. Journal of Psychoactive Drugs: Vol. 17, LSD in Retrospect, pp. 297-303.
Journal of Medicinal Chemistry
May 1, 1982
David E. Nichols, David Harley Lloyd, Andrew J. Hoffman et al.
178 citations
The enantiomers of 3,4-(methylenedioxy)amphetamine (MDA), p-methoxyamphetamine (PMA), and N-Me-MDA (MDMA), along with their alpha, alpha-dimethylated derivatives, were evaluated for an effect on the release of [3H]serotonin from rat whole brain synaptosomes. The amphetamine isomers were all potent in inducing the release of [3H]serotonin at bath concentrations of 1 and 10 micrometers but were...
American Journal of Psychiatry
September 1, 1968
Solomon H. Snyder, Louis A. Faillace, Herbert Weingartner
77 citations
DOM, a hallucinogen related to mescaline and amphetamine and designated "STP" by hippies, along with DOET, the ethyl homologue of DOM, were given in small doses to normal subjects in a double-blind study. Both drugs increased self-awareness and produced mild euphoria but no hallucinogenic or psychotomimetic effects. The two drugs "freed up" subjects' word associations without impairing memory...
Frontiers in Psychology
October 27, 2026
Nasiru Mohammed Abdullahi, Rashid Menhas, Patience Osose Nasir et al.
Background: Clinical research on psychedelic-assisted therapy (PAT) has expanded substantially in recent years, particularly for post-traumatic stress disorder (PTSD) and depressive disorders. Contemporary studies have generally evaluated psychedelic administration within controlled therapeutic settings that include psychological support, preparation, and integration. However, variability in...
Zenodo (CERN European Organization for Nuclear Research)
October 20, 2026
Lara Vervloet Carvalho, Sarah Isabela Magalhães Costa, Nathália Marques Santos et al.
preprint
As terapias assistidas por psicodélicos emergiram, na última década, como estratégia de investigação de destaque para transtornos psiquiátricos refratários às abordagens convencionais. Em ensaio de fase 2 controlado, dose única de 25 mg de psilocibina produziu redução média de 12,0 pontos na escala MADRS em pacientes com depressão resistente ao tratamento, superior à condição controle de 1 mg....